- The disease
- Solid tumours are cancers arising in organs or tissues that form a distinct mass, as opposed to blood cancers. They represent the majority of cancer diagnoses globally. Treatment options vary widely by tumour type, and patients with advanced or treatment-resistant solid tumours often have limited options. The specific tumour type or types targeted by PAT-DX1 in the current programme are .
- What the asset is trying to do
- PAT-DX1 is described by Patrys as a deoxymab, a term the company uses for a class of monoclonal antibodies (laboratory-made proteins designed to bind specific targets on cells). The precise molecular target of PAT-DX1 is not disclosed in the available data. An earlier Patrys antibody, PAT-SM6, targeted a protein called GRP78 and was studied in multiple myeloma (per ClinicalTrials.gov NCT01727778); whether PAT-DX1 shares this target or mechanism is . How PAT-DX1 differs from existing approved antibody therapies in solid tumours is .
- What the trial is measuring, and why it matters
- No PAT-DX1 clinical trial has been identified in the available data; the ClinicalTrials.gov identifier and trial protocol are . For the earlier PAT-SM6 Phase 1 study (NCT01727778), the registered primary focus was drug safety in patients with relapsed or refractory multiple myeloma, with primary completion recorded as April 2014 (per ClinicalTrials.gov NCT01727778). The endpoints, measurement schedule, and patient population for any PAT-DX1 solid tumour trial are .
- Efficacy benchmarks in this setting
- Because the specific solid tumour indication for PAT-DX1 has not been disclosed in the available data, citing relevant approved-therapy benchmarks for response rates or survival in that exact setting is not possible at this time. Once the target indication is confirmed, approved therapies in that setting and their reported efficacy figures (response rates, progression-free survival, overall survival) from published trials or prescribing information should be inserted here. Any early-stage figures from a PAT-DX1 Phase 1 study would not be statistically comparable to those established benchmarks, given differences in trial design, patient selection, and study size.
- Commercial context
- Patrys (ASX: PAB) is an ASX-listed biotechnology company. Based on recent announcements, the company completed a $3.2 million placement in April 2026 to advance clinical trials (per ASX announcement, 19 April 2026). Patrys is also advancing a separate asset, RLS-2201, with a manufacturing and regulatory pathway initiated in March 2026 and a Phase 1 clinical trial flagged as a next step for RLS-2202 (per ASX announcements, 10 March 2026 and 19 May 2026). Whether PAT-DX1 is currently the company's lead asset, and whether any regulatory designations or partnership agreements exist for PAT-DX1 in solid tumours, is . No approved deoxymab therapies for solid tumours have been identified in the available data.